articleMolecular Cancer TherapeuticsJun 22, 2010BRONZE OA

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Merck & Co., Inc., Rahway, NJ, USA (United States)

PubMed
Indexed incrossrefpubmed

Abstract

The serine/threonine kinase Akt lies at a critical signaling node downstream of phosphatidylinositol-3-kinase and is important in promoting cell survival and inhibiting apoptosis. An Akt inhibitor may be particularly useful for cancers in which increased Akt signaling is associated with reduced sensitivity to cytotoxic agents or receptor tyrosine kinase inhibitors. We evaluated the effect of a novel allosteric Akt inhibitor, MK-2206, in combination with several anticancer agents. In vitro, MK-2206 synergistically inhibited cell proliferation of human cancer cell lines in combination with molecular targeted agents such as erlotinib (an epidermal growth factor receptor inhibitor) or lapatinib (a dual epidermal…

Citation impact

936
total citations
FWCI
24.50
Percentile
100%
References
53
Citations per year

Authors

11

Topics & keywords

Keywords
  • Erlotinib
  • Protein kinase B
  • Pharmacology
  • Epidermal growth factor receptor
  • Cancer research
  • Chemistry
  • Biology
  • Signal transduction
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.